You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,323,013


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,323,013
Title:Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
Abstract: Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1P1.
Inventor(s): Del Valle; Juan R. (Tampa, FL), Hu; Chih-Chi Andrew (Tampa, FL)
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL)
Application Number:14/786,561
Patent Claims:1. A compound having Formula IV: ##STR00017## wherein A is an aldehyde, a dioxane, a benzoate, an ester, a carbonyl, a carboxylic acid, CH.dbd.CH--CO.sub.2R.sup.9, or CH.dbd.CHSO.sub.2R.sup.9, where R.sup.9 is H, OH, or alkyl; R.sup.5 is chosen from hydrogen, benzyl, substituted benzyl, benzoate, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkylaryl, aryl, alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, alkyl, amino, amido, --NR.sup.6R.sup.7, --C(O)NR.sup.6R.sup.7, alkoxy, alkylhydroxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; and R.sup.6 and R.sup.7 are independently H, alkyl, or R.sup.6 and R.sup.7 together with the atoms to which they are attached form a 3-7 membered cyclic moiety wherein any of the additional atoms can be heteroatoms and the 3 to 7-membered ring is optionally a heterocyclic structure that is optionally substituted; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, having Formula IV-A, IV-B, or IV-C: ##STR00018##

3. The compound of claim 1, having Formula V: ##STR00019## wherein R.sup.5 is chosen from hydrogen, benzyl, substituted benzyl, acetate, alkyl, substituted alkyl, amidine, or substituted amindine; or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, having Formula VII: ##STR00020## or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, having any one of the following structures: ##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025## wherein Alloc is an allyloxycarbonyl moiety.

6. A pharmaceutical composition comprising a compound of claim 1.

7. The pharmaceutical composition of claim 6, further comprising ibrutinib.

8. A method for treating a disease or pathology in a subject in need thereof, comprising: administering a composition comprising the compound of claim 1.

9. The method of claim 8, wherein the disease is associated with XBP-1s activity.

10. The method of claim 8, wherein the disease is associated with IRE-1RNase activity.

11. The method of claim 8, wherein the disease is associated with upregulation of the IRE-1/XBP-1 pathway.

12. The method of claim 8, wherein the subject has been diagnosed with a B cell cancer.

13. The method of claim 12, wherein the cancer is chronic lymphocytic leukemia.

14. The method of claim 8, wherein the composition further comprises a B cell receptor signaling inhibitor.

15. The method of claim 14, wherein the B cell receptor signaling inhibitor is selected from the group consisting of ibrutinib, CAL-101, or combinations thereof.

16. The method of claim 15, wherein the composition comprises ibrutinib and a compound chosen from Formula IV A, IV-B, IV-C, or any combination thereof.

17. The method of claim 8, further comprising administering an immunotherapeutic agent.

18. The method of claim 17, wherein the immunotherapeutic agent is selected from the group consisting of Infliximab, Basiliximab, Daclizumab, Trastuzumab, Rituximab, Ibritumomab tiutexan, Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, or combinations thereof.

19. The method of claim 8, further comprising administering a chemotherapeutic agent.

20. The method of claim 19, wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, aziathioprine, cyclophosphamide, fludarabine, etoposide, doxorubicin, methotrexate, vincristine, prednisone, carboplatin, cis-platinum, taxol, or combinations thereof.

21. The method of claim 8, wherein the subject has been diagnosed with an inflammatory disease.

22. The method of claim 21, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis or lupus.

Details for Patent 10,323,013

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2033-04-23
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 05/12/1998 ⤷  Try a Trial 2033-04-23
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 01/02/2003 ⤷  Try a Trial 2033-04-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.